Most Australians tracking retatrutide are asking one question: when do we get it? But while we wait, the queue in front of it has changed shape. In 2026 the next wave of obesity medicines heading for the Therapeutic Goods Administration isn't another injection — it's tablets. That reframes the whole retatrutide vs Wegovy comparison for Australians, because the drug you can realistically start in 2027 may be a pill you swallow, while the strongest weight-loss numbers ever recorded still sit inside an investigational injection that hasn't been filed with any regulator yet.

Retatrutide vs Wegovy: the queue Australians are actually standing in

Here's the current state of play, plainly:

  • Wegovy (semaglutide) is TGA-registered for weight management. It targets one receptor, GLP-1.
  • Mounjaro (tirzepatide) is TGA-registered and hits two receptors, GLP-1 and GIP.
  • Retatrutide is Eli Lilly's triple agonist — GLP-1, GIP and glucagon. It is investigational, not TGA-approved, and Lilly has said it plans to submit a biologics licence application to the US FDA in the first quarter of 2027, with other regulators following.

Layered on top of that, 2026 brought a new front: oral obesity drugs. Australian pharma trade reporting in August 2026 said Novo Nordisk has applied to the TGA for its oral Wegovy, and that Lilly had already lodged its own oral GLP-1 (orforglipron) with the regulator back in January. Neither is a triple agonist. Both are, in regulatory terms, much further down the track here than retatrutide.

So the honest version of "retatrutide vs Wegovy" for an Australian in mid-2026 isn't a head-to-head efficacy shootout. It's a timing question: a moderate-to-strong option you can access now or soon, versus a stronger option whose Australian paperwork hasn't started.

What the numbers do and don't say

Retatrutide's phase 3 TRIUMPH-1 readout reported up to around 28.3% average body weight reduction at the 12mg dose over 80 weeks, with 45.3% of participants losing 30% or more of their body weight. Semaglutide's registration trials sit in the mid-teens for average loss; tirzepatide lands around the low twenties at top dose. On paper, that's a meaningful gap.

Three caveats matter, and anyone selling you certainty is skipping them:

  1. These are different trials, different populations and different eras — not a randomised head-to-head. Cross-trial comparisons flatter the newest drug almost every time.
  2. Much of the retatrutide phase 3 detail has reached the public through company announcements and conference presentations ahead of full peer-reviewed publication of every endpoint. That's normal, but it means the fine print can still shift.
  3. Average results are not your result. Trial averages are built on structured dosing, regular reviews and high adherence — conditions most real-world patients don't get. We've written more about that in clinical trials.

Oral drugs change the equation differently again. Their headline weight loss is generally lower than the best injectables, but a tablet removes needles, removes cold-chain hassle, and is far easier to scale in manufacturing — which historically is what breaks supply in Australia.

The Australian implication: adherence beats theoretical maximum

Australia has a genuine problem to solve — roughly 66.8% of adults are living with overweight or obesity — and access here is shaped less by which molecule is strongest than by what's registered and what's subsidised.

Right now, that's the pinch point. The PBAC has publicly grappled with equitable access to GLP-1 obesity treatments, and as of 2026 the injectable weight-management options remain private-script purchases for most Australians, with monthly costs commonly quoted in the low hundreds and rising with dose. That out-of-pocket reality is exactly why a cheaper, easier-to-supply tablet could win real-world market share even if it loses on the scales.

For retatrutide, the practical Australian read-through:

  • Don't put your health on hold waiting for it. A drug with no TGA submission is years from a pharmacy shelf here, and a rejection or delay anywhere in the chain pushes it further.
  • What you do with an existing therapy is not wasted. Dose titration experience, tolerating GI side effects, protein intake, resistance training and bloodwork all transfer to a future medicine.
  • Expect sequencing, not switching. If retatrutide is eventually registered here, the likeliest early candidates are people with high complication burden who haven't got enough benefit from existing options — a pattern already visible in how Lilly structured its overseas early-access criteria in August 2026.

More on local timelines in our Australia guide, and on the mechanism itself in what is retatrutide.

Side effects: the comparison people forget to make

Across retatrutide's trials the most common adverse events were gastrointestinal — nausea, diarrhoea, constipation and reduced appetite — the same family of effects that dominates semaglutide and tirzepatide reporting. Adding a glucagon arm brings its own considerations to watch in longer follow-up, including heart rate and how the drug behaves in people with liver or kidney disease. Nothing here suggests retatrutide is a gentler drug than what's already registered in Australia; it suggests a stronger drug with a familiar tolerability profile. Our safety page tracks what's been reported so far.

Australian-specific point: the TGA has issued advice for the GLP-1 class covering matters such as mood-related warnings and possible effects on oral contraception. Class-level guidance like that tends to follow a molecule into new markets, so expect Australian product information for any triple agonist to carry the class warnings plus whatever the glucagon component adds.

Bottom line

Retatrutide looks like the most powerful weight-loss medicine in late-stage development. It is also the furthest from an Australian pharmacy counter of any of the options in this article. If your decision window is 2026 or 2027, you're realistically choosing between registered injections and the incoming oral wave — with retatrutide as the upgrade path you position yourself for, not the plan you wait on.

Want the next TGA or TRIUMPH development in your inbox the day it lands? Join the free updates list.

FAQ

Is retatrutide better than Wegovy?

In trial data, retatrutide has reported substantially higher average weight loss — up to about 28.3% at 12mg over 80 weeks, versus mid-teens percentages for semaglutide. But these come from separate trials, not a direct head-to-head, and retatrutide is still investigational and not TGA-approved.

Can I get retatrutide instead of Mounjaro in Australia?

No. Mounjaro is TGA-registered and available on private prescription, while retatrutide has no TGA registration and no submission lodged in Australia. Any comparison is currently theoretical for Australian patients.

Will retatrutide come as a tablet?

There's no oral retatrutide in late-stage development. Retatrutide is a once-weekly injectable peptide; the oral obesity drugs heading for the TGA in 2026 are different molecules, including Novo Nordisk's oral semaglutide and Lilly's orforglipron.

When will retatrutide be available in Australia?

There's no confirmed date. Eli Lilly has signalled a US regulatory filing from 2027, and TGA evaluation plus any PBS decision would follow after that, so Australian availability realistically sits well beyond 2027.

Sources

This article is general information, not medical advice. Retatrutide is investigational and not approved by the TGA; do not make treatment decisions based on this page — speak with your GP or a qualified health practitioner. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly, Novo Nordisk or any pharmaceutical company.